Legal status in the United States
Is Orforglipron legal?
Read at FDA, DEA and WADAPublished by PepVault
Orforglipron is FDA-approved (Foundayo, first in 2026), is not a federally controlled substance, and is not named on WADA’s Prohibited List, as of November 18, 2026.
Orforglipron at a glance
| Check | Status, read Nov 18, 2026 |
|---|---|
| FDA approval | Approved (Foundayo, 2026) |
| Compounding | Component of an approved drug (503A condition) |
| DEA schedule | Not controlled |
| Sport (WADA) | Not named on the list |
FDA approval
Orforglipron is FDA-approved as Foundayo, a daily tablet, since April 2026.
Foundayo (tablet)
Approved for weight loss and keeping it off, in adults with obesity or with excess weight and a weight-related condition. NDA 220934, first approved April 1, 2026.
- Drugs@FDA: Foundayo, application 220934, U.S. Food and Drug Administration. Read .
- Foundayo prescribing information on DailyMed, National Library of Medicine (DailyMed). Read .
- Drugs@FDA: Foundayo, application 220934, U.S. Food and Drug Administration. Read .

Compounding
Orforglipron is the active ingredient of an FDA-approved drug (Foundayo). FDA’s page on bulk drug substances gives three conditions under section 503A for a substance a pharmacy compounds from, and one of them is being a component of an FDA-approved drug product; the 503A and 503B bulks lists don’t name orforglipron.
The source: “Are components of FDA-approved drug products if an applicable USP or NF monograph does not exist”
- Bulk Drug Substances Used in Compounding (content current as of March 26, 2026), U.S. Food and Drug Administration. Read .
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026), U.S. Food and Drug Administration. Read .
- 503B Bulk Drug Substances List (content current as of May 16, 2024), U.S. Food and Drug Administration. Read .
DEA schedule
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
- 21 CFR Part 1308, Schedules of Controlled Substances (eCFR, up to date as of November 16, 2026), Electronic Code of Federal Regulations. Read .
- Controlled Substances, Alphabetical Order (dated November 17, 2026), Drug Enforcement Administration, Diversion Control Division. Read .
Sport (WADA)
The 2026 Prohibited List doesn’t name orforglipron or GLP-1 drugs, and S0, the class for unapproved substances, doesn’t reach an approved drug.
- World Anti-Doping Code International Standard, Prohibited List 2026 (in effect from January 1, 2026), World Anti-Doping Agency. Read .
What this means and doesn’t
This page reports what the agencies’ own pages said about Orforglipron in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.
It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.
Questions
Is Orforglipron FDA approved?
Orforglipron is FDA-approved as Foundayo, a daily tablet, since April 2026.
Is Orforglipron a controlled substance?
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
Is Orforglipron banned in sport?
The 2026 Prohibited List doesn’t name orforglipron or GLP-1 drugs, and S0, the class for unapproved substances, doesn’t reach an approved drug.
What does FDA say about compounding Orforglipron?
Orforglipron is the active ingredient of an FDA-approved drug (Foundayo). FDA’s page on bulk drug substances gives three conditions under section 503A for a substance a pharmacy compounds from, and one of them is being a component of an FDA-approved drug product; the 503A and 503B bulks lists don’t name orforglipron.